Shares of Reynolds Consumer Products (REYN) surged over 16% following a Q4 earnings beat, driven by robust revenue and cash flow. However, the company's tempered guidance for the coming year casts a shadow on the celebratory rally, highlighting investor focus on immediate financial health over future projections.
Sonos stock climbed over 4% after the audio specialist's latest earnings report showcased a dramatic expansion in profitability, significantly exceeding Wall Street forecasts despite flat year-over-year revenue.
Azenta's stock tumbled sharply after its Q4 results revealed a significant shortfall in a key profitability metric, despite revenue meeting expectations, sparking a major sell-off.
Shares of food distribution leader Performance Food Group (PFGC) plunged more than 7% Thursday following a double miss on quarterly earnings and revenue, coupled with a subdued profit forecast that rattled investor confidence.
Boston Scientific shares tumbled nearly 14% Thursday after the medical device giant's first-quarter guidance fell short of expectations, sparking a sell-off despite the company posting better-than-expected fourth-quarter earnings.
Shares of packaging giant Silgan Holdings jumped more than 7% after the company's fourth-quarter earnings and revenue topped Wall Street forecasts, providing a welcome boost following a period of investor caution over its financial guidance.
Shares of defense electronics firm Mercury Systems (MRCY) cratered Thursday, despite reporting Q4 results that topped analyst estimates. The steep sell-off was driven by mounting investor alarm over deteriorating operating margins and cash flow, highlighting deeper structural challenges within the business.
Shares of residential solar leader Sunrun surged over 11% after announcing the nation's largest distributed power plant, with customer participation skyrocketing more than fivefold in 2025 and delivering gigawatt-scale grid support.
Novo Nordisk announced Wednesday the upcoming U.S. launch of its oral semaglutide tablets under the Ozempic brand, with FDA approval secured for multiple doses. The move marks a significant shift for the popular diabetes treatment from injection to pill form.
Amid market volatility, one investor outlines a strategic pivot towards Brookfield Renewable, Hormel Foods, and Clorox, betting on their resilient dividends and growth potential.
Crude oil futures showed minimal movement Thursday, caught between hopes for eased Middle East tensions from upcoming diplomatic talks and supportive supply data. Gasoline futures edged higher as traders weighed mixed signals from inventories and geopolitics.
Amazon's acquisition of a documentary on the sitting First Lady has sparked debate over corporate influence, while analysts see potential long-term benefits far exceeding its box office performance.
Varo Bank has closed a $123.9 million Series G round led by Warburg Pincus and Coliseum Capital, while adding seasoned executives from Morgan Stanley and JPMorgan Chase to its board as it navigates growth amid ongoing losses.
A poignant national touring exhibition, born from a mother's grief for her son Oscar Grant, uses birthday remembrances to humanize victims of police brutality and examine the enduring impact on communities.
Former Bolivian leader Evo Morales has vanished from public view for over a month, coinciding with an active arrest warrant and the controversial reinstatement of U.S. drug enforcement agents to the country, fueling speculation and political tension.
The U.S. Supreme Court has declined to block California's newly adopted congressional district map, a move seen as countering Republican redistricting efforts in Texas. The decision is expected to bolster Democratic prospects in the battle for control of the House of Representatives in the upcoming midterm elections.
As reproductive rights face escalating legal threats, personal finance experts are advising clients to prioritize dedicated savings for abortion access—a stark reflection of America's shifting healthcare landscape.
Novo Nordisk reports unprecedented early uptake of its oral Wegovy, with weekly prescriptions hitting 50,000 within weeks of its U.S. debut. The pill's lower price and convenience are broadening access to GLP-1 treatments amid a rapidly evolving market.
As Bitcoin struggles below $76,000, industry titans Mike Novogratz and Michael Burry offer starkly contrasting outlooks. This analysis delves into their arguments, the impact of ETFs, and a broader macroeconomic theory that could redefine Bitcoin's role between 'inside' and 'outside' money.
A coalition of major investors has filed resolutions challenging BP's pivot back toward oil and gas, demanding greater transparency on capital allocation and how the strategy aligns with earlier climate pledges ahead of the annual meeting.
